Clinical Research Directory
Browse clinical research sites, groups, and studies.
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Sponsor: AstraZeneca
Summary
To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use
Official title: General Use-Results Study of Calquence Capsules 100 mg in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
67
Start Date
2023-06-19
Completion Date
2025-08-20
Last Updated
2026-05-15
Healthy Volunteers
No
Locations (15)
Research Site
Aichi, Japan
Research Site
Chiba, Japan
Research Site
Fukuoka, Japan
Research Site
Hyōgo, Japan
Research Site
Kanagawa, Japan
Research Site
Kyoto, Japan
Research Site
Miyazaki, Japan
Research Site
Nagano, Japan
Research Site
Nara, Japan
Research Site
Okayama, Japan
Research Site
Osaka, Japan
Research Site
Saitama, Japan
Research Site
Shizuoka, Japan
Research Site
Tokyo, Japan
Research Site
Yamanashi, Japan